TAXUS STENT DEMONSTRATES EXCELLENT EFFICACY AND SAFETY IN INDEPENDENT 'STENT' REGISTRY
Angiotech Pharmaceuticals' corporate partner, Boston Scientific, welcomed interim
results from the independent, multicenter stent registry that further demonstrate
the efficacy and safety of Boston Scientific's Taxus Express(2) paclitaxel-eluting
coronary stent system among real-world patients with blocked coronary arteries.